BioPharma Resources

Drug Trial Radar · NCT07665437

An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS

A Double-blind, Double-dummy, Parallel Group, Multicenter Phase 3 Extension Study Evaluating the Long-term Safety and Efficacy of 2 Doses of Remibrutinib in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 710 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

710

Planned (sponsor's estimate)

Start

Jul 10, 2026

Primary completion

Oct 15, 2031

Study completion Oct 15, 2031

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Jun 24, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the long-term safety, tolerability and efficacy of remibrutinib (LOU064) in adult participants with moderate to severe hidradenitis suppurativa (HS) who have completed either of the preceding Phase 3 studies, CLOU064J12301 or CLOU064J12302.

Conditions

  • Hidradenitis Suppurativa

Interventions

  • RemibrutinibDrug

    Remibrutinib Dose A and B (oral)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Baseline, up to Week 280

Locations

61 sites in 12 countries. Site status is shown where the registry gives one.

  • Total Skin and Beauty Dermatology Center PC

    Birmingham, Alabama · Recruiting

  • Johnson Dermatology

    Fort Smith, Arkansas · Recruiting

  • Arkansas Research Trials

    North Little Rock, Arkansas · Recruiting

  • Ctr for Dermatology Clinical Res

    Fremont, California · Recruiting

  • USC Keck School of Medicine

    Los Angeles, California · Recruiting

  • Olive View UCLA Medical Center

    Sylmar, California · Recruiting

  • Clinical Trials Research Institute

    Thousand Oaks, California · Recruiting

  • University of MiamiHealth System

    Miami, Florida · Recruiting

  • Floridian Research Institute

    Miami, Florida · Recruiting

  • University Of South Florida

    Tampa, Florida · Recruiting

  • Endeavor Health

    Glenview, Illinois · Recruiting

  • Dundee Dermatology

    West Dundee, Illinois · Recruiting

  • Southern IN Clinical Trials

    New Albany, Indiana · Recruiting

  • Revival Research Institute

    Troy, Michigan · Recruiting

  • Skin Specialists PC

    Omaha, Nebraska · Recruiting

  • Cameron Dermatology

    New York, New York · Recruiting

  • Icahn School Of Med At Mount Sinai

    New York, New York · Recruiting

  • Skinsearch of Rochester Inc

    Rochester, New York · Recruiting

  • OnSite Clinical Solutions LLC

    Huntersville, North Carolina · Recruiting

  • Optima Research Boardman

    Boardman, Ohio · Recruiting

  • Apex Clinical Research Center LLC

    Mayfield Heights, Ohio · Recruiting

  • UP Medical Center H System

    Pittsburgh, Pennsylvania · Recruiting

  • Clinical Research Ctr of Carolinas

    Charleston, South Carolina · Recruiting

  • Medical University of South Carolina MUSC

    Charleston, South Carolina · Recruiting

  • RFSA Dermatology

    San Antonio, Texas · Recruiting

  • Center for Clinical Studies-Lee

    Webster, Texas · Recruiting

  • Forefront Dermatology

    Vienna, Virginia · Recruiting

  • Novartis Investigative Site

    CABA, Argentina · Recruiting

  • Novartis Investigative Site

    CABA, Argentina · Recruiting

  • Novartis Investigative Site

    Caba, Buenos Aires, Argentina · Recruiting

  • Novartis Investigative Site

    CABA, Buenos Aires, Argentina · Recruiting

  • Novartis Investigative Site

    Rosario, Santa Fe Province, Argentina · Recruiting

  • Novartis Investigative Site

    Sydney, New South Wales, Australia · Recruiting

  • Novartis Investigative Site

    Melbourne, Victoria, Australia · Recruiting

  • Novartis Investigative Site

    Parkville, Victoria, Australia · Recruiting

  • Novartis Investigative Site

    Edmonton, Alberta, Canada · Recruiting

  • Novartis Investigative Site

    London, Ontario, Canada · Recruiting

  • Novartis Investigative Site

    Montreal, Quebec, Canada · Recruiting

  • Novartis Investigative Site

    Québec, Quebec, Canada · Recruiting

  • Novartis Investigative Site

    Beijing, China · Recruiting

Showing 40 of 61 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.